Last reviewed: June 2, 2026
Last updated: June 2, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
GLP-1 receptor agonist eligibility typically requires a BMI of 27 or higher with a weight-related condition, or BMI of 30 or higher regardless of comorbidity. However, medical eligibility extends beyond these thresholds to include comprehensive metabolic assessment, cardiovascular health, kidney function, and individual treatment goals.
Understanding what qualifies you for GLP-1 therapy involves both standard clinical criteria and emerging insight into how your body may respond to treatment. Genetic factors in your GLP-1 receptor pathway, GIPR signaling, and metabolic regulators can provide valuable context for personalized conversations with your healthcare provider about treatment fit and expectations.
Primary Medical Eligibility Criteria
FDA-approved GLP-1 medications require either a BMI of 30 kg/m² or greater, or BMI of 27 kg/m² with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Some patients with prediabetes or metabolic dysfunction qualify under specific circumstances. Your provider assesses whether these criteria apply to your individual situation.
Beyond BMI, eligibility hinges on comprehensive health screening including HbA1c levels, fasting glucose, lipid panels, and cardiovascular status. Kidney function (eGFR) must be adequate, as GLP-1 medications can affect renal perfusion. Thyroid function, gastrointestinal history, and family history of medullary thyroid carcinoma are also reviewed before treatment initiation.
Metabolic and Cardiovascular Assessment Framework
A complete eligibility evaluation includes metabolic markers that predict treatment response and safety outcomes. This framework helps providers identify who benefits most from GLP-1 therapy and who may require closer monitoring or dosage adjustments during treatment.
|
Assessment Category |
What Providers Evaluate |
| Metabolic Status |
HbA1c, fasting glucose, HOMA-IR, lipid profile, baseline weight |
| Cardiovascular Health |
Blood pressure, EKG findings, prior cardiac events, heart failure status |
| Renal Function |
eGFR (>30 mL/min/1.73m² generally safe), albumin, proteinuria |
| GI and Endocrine History |
Pancreatitis, gastroparesis, thyroid nodules, family history of MTC |
Contraindications and Safety Barriers
Certain medical conditions preclude GLP-1 use. Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and severe diabetic retinopathy requiring immediate intervention. Relative contraindications such as severe gastroparesis or active pancreatitis require provider discussion and risk-benefit assessment.
Pregnancy, breastfeeding, and recent bariatric surgery may warrant deferral or careful monitoring. Patients with a history of suicidal ideation should discuss GLP-1 use with their mental health provider, as mood-related side effects have been observed in some cases. Open communication with your healthcare team about medication history and medical conditions ensures safe, appropriate treatment.
Genetic Predispositions and Treatment Context
Emerging research reveals that variations in GLP-1 receptor (GLP1R), glucose-dependent insulinotropic peptide receptor (GIPR), and metabolic regulators like FTO and MC4R influence how individuals respond to peptide-based therapies. These genetic predispositions can help contextualize expected response patterns and may inform dosing strategy conversations with your provider.
Genetic insights do not predict exact medication response or guarantee outcomes. Instead, they provide a framework for understanding individual metabolic phenotypes and can support more targeted treatment discussions. When combined with clinical assessment, genetic context may help explain why some patients respond robustly to certain GLP-1 compounds while others benefit from alternative formulations or dosing approaches.
How PlexusDx Supports a More Personalized Approach
PlexusDx recognizes that standard eligibility criteria provide a foundation, but personalized precision medicine can add valuable clinical context. Our Precision Peptide Genetic Test reveals predispositions in key peptide pathways—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—that may help provide context for how your metabolic system responds to GLP-1 treatment. This information should always be interpreted with a qualified healthcare provider.
The Precision Peptide Genetic Test is a $99 add-on available after your first month of treatment and focuses on predispositions in peptide genetic pathways rather than traditional pharmacogenomic response. By identifying your individual predisposition profile, you and your provider can have a more informed conversation about which compounded GLP-1 formulation, dosing strategy, or dual-compound options (like GLP-Squared) may align best with your genetic context and clinical goals.
Whether you choose compounded semaglutide injection starting at $149/month, oral semaglutide at $249/month, compounded tirzepatide at $249/month, or our dual-compound GLP-Squared options, pairing treatment with genetic insight can support a more personalized approach. This framework helps ensure your eligibility assessment and treatment plan reflect both standard clinical criteria and your individual peptide pathway predispositions.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
GLP-1 Medication Costs: Pricing Models & Personalization
Popcorn on Ozempic: Safe Snacking Guide for GLP-1 Users